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1. Introduction 
The survival of patients with colorectal cancer (CRC) has increased constantly for many 
years due to superior surgical techniques, improved postoperative care, regular follow-up 
and an increased use of effective systemic therapy in the adjuvant and the palliative setting  
[1,2]. All of these advancements are important, but the establishment of multidisciplinary 
teams which facilitate optimal selection of therapy for individual patients may have been 
the most important concept on its own. 
In recent years a number of biologically active substances attacking specific signalling 
pathways in cancer cells (targeted therapy) have been developed and included in the 
treatment of patients with CRC.  Three monoclonal antibodies (cetuximab, panitumumab, 
bevacizumab) have by now been approved for therapy in metastatic CRC (mCRC) [2,3].  
Angiogenesis is necessary in tumour development and controlled in part by the vascular 
endothelial growth system which is inhibited by bevacizumab (Avastin ®) and many other 
anti-angiogenic drugs.  
Cetuximab (Erbitux®) and panitumumab (Vectibix®) block the extracellular portion of the 
epidermal growth factor receptor (EGFR) and these two drugs will be discussed in detail in 
this chapter.  
2. Targeted therapy - Inhibition of EGFR  
EGFR is a trans-membrane glycoprotein that is involved in signaling pathways affecting 
cellular growth, differentiation, and proliferation and EGFR is expressed in many types of 
normal tissues. The EGFR is up regulated in a large number of cancers, in CRC in 60-80% of 
cases, and might be associated to a poor prognosis. Once a ligand binds to the extracellular 
domain of EGFR, receptor-dimerization occurs and down-stream signaling cascades are 
activated. Amongst the downstream effectors are the RAF/MEK/MAPK pathway and the 
PI3K/PTEN/AKT pathway.  
Two anti-EGFR monoclonal antibodies are approved by US Food and Drug Administration 
and European Medicines Agency for the treatment of CRC – cetuximab and panitumumab. 
Both are directed against the ligand-binding site of EGFR and competitively inhibiting 
ligand-induced activation, and thereby inhibiting EGFR induced cell growth, survival, and 
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proliferation. In addition, cetuximab may act by inducing an antibody-dependent cell-
mediated cytotoxicity reaction as cetuximab is an IgG1 antibody.  
Cetuximab is a human-murine chimeric monoclonal antibody with terminal half-life around 
4-5 days (range 3-7 days) whereas panitumumab is a fully humanized IgG2 monoclonal 
antibody with terminal half-life around 7 days (range 4-11 days). 
3. Predicting efficacy of anti-EGFR therapy 
Unfortunately only a fraction of patients will benefit from the EGFR inhibition and therefore 
much research is ongoing to identify predictive markers in order to tailor therapy for the 
individual patient.  
Several studies have shown a clear correlation between the severity of skin rash and 
outcome of therapy of the anti-EGFR antibodies [4-7].  
In addition, development of hypomagnesaemia may be a surrogate marker for outcome of 
therapy [8,9]. 
Until recently, the development of skin rash during therapy was the most promising 
predictive factor, but focus has now changed towards assessment of tumour tissue. 
Predicting efficacy of anti-EGFR treatment is naturally focused on the EGFR and effectors in 
the down-stream-signaling pathways in the tumour. Even though EGFR is the target of the 
anti-EGFR antibodies there is no difference in efficacy in patients with EGFR positive and 
EGFR negative tumours as assessed by immunohistochemistry [10] and therapy is therefore 
not restricted to tumours overexpressing EGFR. 
KRAS is a member of one of the intra-cellular signal-transduction cascades. If KRAS harbors 
a mutation (KRASmut), then the growth signal is constitutively activated independently of 
ligand binding to the extracellular part of the receptor.  
KRASmut is found in approximately 40% of mCRC patients [11].The KRAS mutation is an 
early event during the colorectal adenoma-carcinoma carcinogenic process [12] and thus 
there is a high concordance between KRAS mutations in the primary tumour and the 
metastasis [13]. Analyses of clinical trials with anti-EGFR antibodies in mCRC have 
demonstrated that the KRAS mutational status is central for the effect of anti-EGFR 
treatment. Patients with KRASmut do not or hardly ever respond to anti-EGFR therapy and 
progression-free survival (PFS) and survival is definitely shorter than in patients with KRAS 
wildtype tumours (KRASwt) [5,11,14-19]. However, recently it has been suggested that the 
different KRAS mutations might have different biological potentials, and that patients with 
codon 13 mutated tumours may be sensitive to therapy with cetuximab [20]. 
Normal expression and mutation status of other members of the down-stream signaling 
pathways (e.g. BRAF PTEN and PI3K), are also needed for normal function of the EGFR 
pathway. In a recent study including more than 600 patients with mCRC treated with 
cetuximab and irinotecan in the third line setting response rates were as high as 41 % in the 
population of patients with wildtype KRAS, BRAF, NRAS, and PIK3CA exon 20 compared 
to 24% in the unselected population [11]. 
Furthermore many other attempts have been made in order to identify other predictive 
marker including of expression of ligands to the EGFR, mutations in the EGFR resulting in 
structural changes in the receptor, expression of other members of the EGFR-family; 
however currently the K-RAS gene mutational status is the only established marker of 
sensitivity to panitumumab and cetuximab, and the use of anti-EGFR antibodies should be 
restricted to patients with KRASwt tumours. 
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4. Adjuvant therapy 
4.1 Adjuvant chemotherapy after radical resection for colon cancer  
Adjuvant fluoropyrimidine-based chemotherapy for 6 months is standard of care in patients 
with radical resected stage III colon cancer, whereas it is more controversial in patients with 
stage II colon cancer. Modest but definite benefit of 4-5 % in 5-years survival has been 
demonstrated in pooled analyses and in the Quasar study [21-24]. 
Three large phase III trials have documented that addition of oxaliplatin to 
fluoropyrimidine (FOLFOX, FLOX, XELOX) are superior compared to single agent 
fluoropyrimidine in terms of disease-free survival and overall survival in stage III patients 
and probably also in high-risk stage II [25-27]. 
4.2 Adjuvant targeted therapy after radical resection for colon cancer  
Cetuximab has been tested in the adjuvant setting. The US Intergroup N0147 study assessed 
the potential benefit of cetuximab added to adjuvant FOLFOX after resection in patients 
with colon cancer stage III. The primary end point was 3 year disease-free survival. The 
initial concept was to treat patients regardless of KRAS status, but when the impact of KRAS 
status in the metastatic setting was established NO147 was amended to include only 
patients with KRAS wild type tumours. In 717 patients with KRAS mutations included 
before amendment both 3-year disease-free survival (FOLFOX: 75.8% versus FOLFOX + 
cetuximab: 72.3%) and 3-year survival (88.0% versus 80.4%) favoured FOLFOX alone [28]. 
Surprisingly, the addition of cetuximab to FOLFOX in the KRAS wild-type population did 
not add any benefit as well , with a 3-year disease-free survival of 75.8% in the FOLFOX arm 
versus 72.3% in the FOLFOX-cetuximab arm [29]. 
The FOxTROT trial is presently evaluating a neo-adjuvant strategy with oxaliplatin-based 
chemotherapy with or without panitumumab in patients with high-risk but resectable colon 
cancer.  
Data from ongoing or completed adjuvant trials are awaited, but currently cetuximab, 
panitumumab and other targeted therapies should not be used outside clinical trials. 
5. Systemic treatment of metastatic colorectal cancer  
Since the introduction of 5-fluorouracil in 1957, numerous well-conducted phase III studies 
have proven its efficacy and even nowadays fluoropyrimidine is the backbone of systemic 
therapy [30,31]. The era of modern combination therapy started when it was shown that 
irinotecan prolonged survival in patients with fluoropyrimidine-resistant disease. Since then 
irinotecan, oxaliplatin, and two oral formulations of 5-fluorouracil (capecitabine and uftoral) 
have been approved [32] and are used in the routine clinical practise. 
Combination chemotherapy with fluoropyrimidine and irinotecan (e.g. FOLFIRI or XELIRI) 
or oxaliplatin (e.g. FOLFOX or XELOX) produces tumour regression in approximately half 
of patients with mCRC. PFS is prolonged from 6 to 9 months and the use of several 
sequential lines of chemotherapy has improved median survival from 6 months to more 
than 18 months.  
When planning the treatment strategy for an individual patient in the daily clinic it is 
important to realize the goal of treatment – is there a possibility for cure or is the treatment 
of palliative character – which depends on the resectability of the metastases and on patient-
related factors as performance status and co-morbidity. 
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Patients with mCRC may be grouped according to the resectability of their metastases: 
resectable at diagnosis and initially unresectable. Patients with initially unresectable mCRC 
can be further subdivided into two groups: potential resectable mCRC which may become 
resectable after tumour shrinkage and non-resectable which is defined as unresectable 
despite major tumour regression [33]. This classification has to be done in a close 
collaboration between surgeons, oncologists, radiologist and pathologist – in a 
multidisciplinary team. For patients with non-resectable mCRC therapy is primarily of 
palliative character.  
In patients with potential resectable or symptomatic mCRC, tumour shrinkage is absolutely 
mandatory and therefore the most effective combination should be used as initial therapy. 
However, in patients with unresectable mCRC AND no tumour-related symptoms a 
sequential approach (single agent immediately followed by combination therapy upon 
progression) seems to be a safe strategy.  
Targeted therapy enhance efficacy of chemotherapy but should be restricted to selected 
patients.  
6. EGFR inhibition in patients with chemoresistent mCRC  
There are no established cytotoxic drugs or combination in the third-line settings after 
progression to irinotecan, oxaliplatin and fluoropyrimidine, but this changed dramatically 
when efficacy of EGFR inhibition was proven in patients with chemo-resistant mCRC [2,3]. 
Data are summarized in Table 1.  
The promising activity observed in phase I and II studies was first confirmed in the pivotal 
BOND study [34] where 329 patients with irinotecan-resistant mCRC were randomised to 
receive either weekly single agent cetuximab alone or cetuximab in combination with 
irinotecan. This combination significantly increased response rate from 11% to 23% and 
prolonged PFS from 1.5 months to 4.1 months. Survival was not significantly prolonged, 
perhaps due to cross-over and use of combination therapy as salvage therapy. As a result of 
the BOND study, cetuximab was approved for patients with irinotecan-resistant disease in 
US and Europe in 2004.  
One of the criticisms of the BOND study was the lack of a control group and therefore 
NCIC-CO.17 was planned and completed [35]. Patients pre-treated with irinotecan and 
oxaliplatin were randomised to receive best supportive care (BSC – no crossover upon 
progression) or cetuximab monotherapy. Compared to BSC, cetuximab prolonged OS from 
4.6 months to 6.1 months (Table 1).  
In a parallel study, a similar benefit in terms of response and PFS was established for 
panitumumab [6]. In contrast to NCIC-CO.17, OS was not significantly prolonged perhaps 
due to the possibility of cross-over to panitumumab after progression in patients 
randomized to BSC. Based on these data, panitumumab was approved for monotherapy of 
refractory mCRC by the US Food and Drug Administration in September 2006 and 
conditionally approved in patients with tumours harbouring wild-type KRAS by the 
European Medicines Agency in December 2007. Presently there are more data on the 
combination of irinotecan and cetuximab as salvage therapy but it may be expected that 
efficacy of irinotecan and panitumumab will be comparable. Indirectly these data suggested 
that irinotecan with cetuximab (and perhaps irinotecan with panitumumab) increase 
response rate to more than 20%, prolong PFS from less than 2 months to more than 4 
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months and that OS is prolonged from around 5 months to 9 months, in patients treated 
unaided by KRAS status. 
 
Author. year Regimen KRAS 
No of 
patients 
RR 
(%) 
Median PFS 
(months) 
Median OS 
(months) 
Third line therapy 
Jonker et al 
NEJM 2007 
BSC ? 285 0 1.8 4.6 
Cet ? 287 7* 1.9* 6.1* 
Karapetis et al 
NEJM 2008 
BSC WT 113 0 1.9 4.8 
Cet WT 117 13* 3.8* 9.5* 
Van Cutsem 
JCO 2007 
BSC ? 232 0 1.7 6.5 
Pan + BSC ? 231 10* 1.8* 6.5 
Amado et al 
JCO 2008 
BSC WT 119 0 1.7 7.6 
Pan + BSC WT 124 17* 2.8* 8.1 
Cunningham et al 
NEJM 2004 
Cet ? 111 11 1.5 6.9 
Cet + Iri ? 218 23* 4.1* 8.5 
Di Fiore et al 
ASCO 2008 
Weekly Cet + 
Iri 
MUT 
281 
0 2.7 8.0 
Weekly Cet + 
Iri 
WT 43* 5.5* 13.2* 
Jensen et al 
ASCO 2010 
Biweekly Cet 
+ Iri 
MUT 
165 
3 3.9 7.9 
Biweekly Cet 
+ Iri 
WT 23* 5.5* 12.1* 
Second line therapy 
EPIC 
Sobrero et al 
JCO 2008 
Iri ? 650 4 2.6 10.0 
Cet + Iri ? 648 16* 4.0* 10.7 
181 
Peeters et al 
JCO 2010 
FOLFIRI WT 294 10 3.9 12.5 
FOLFIRI + 
Pan 
WT 303 35* 5.9* 14.5 
FOLFIRI MUT 248 14 4.9 11.1 
FOLFIRI + 
Pan 
MUT 238 13 5.9 11.8 
Table 1. Selected studies evaluating efficacy of EGFR-inhibition (cetuximab or 
panitumumab) in patients with chemo-resistent mCRC. 
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In the second line setting, the EPIC and “181” studies (Tables 1) showed that irinotecan + 
cetuximab or FOLFIRI + panitumumab, respectively, significantly increased response rate. 
PFS was prolonged significantly in both studies but the higher response rate and longer PFS 
did not translate into an improvement in OS [36,37]. 
7. EGFR inhibition in patients with chemo-naïve mCRC 
Excellent efficacy in patients with chemo-resistent mCRC started logically a number of 
phase II studies for chemotherapy-cetuximab or panitumumab combinations with response 
rates as high as 80%, high liver resection rates and long survival [38]. As a consequence of 
these promising data, phase III studies were planned and conducted (Table 2). All published 
randomized trials were initiated and started before the importance of KRAS was known and 
therefore these studies have included patients with both KRASwt and KRASmut. As 
described efficacy of EGFR monoclonal antibodies is restricted to patients with KRASwt 
however for comparison, data on patients with KRASmut are included in Table 2 but only 
data on KRASwt will be discussed. 
Most trials combining anti-EGFR treatment with chemotherapy confirmed a much higher 
response rate (absolutely 10-20% difference) in the combination arm and most trials also 
showed that PFS was prolonged absolutely 1-2 months but this difference was not as long as 
anticipated or hoped. However, at this time only one phase III study could confirm that the 
benefit in response and PFS was translated to a significant and clinical meaningful 
improvement in survival [19]. 
In the CRYSTAL study more than 1200 patients with EGFR-expressing mCRC were 
randomised to FOLFIRI or FOLFIRI + cetuximab [19]. The investigators managed to collect 
tumour tissue and analyze KRAS status in an astonishing 89% of all patients. Response rate 
and resection rate was significantly higher and both median PFS (8.4 vs. 9.9 months) and 
median survival were significantly prolonged (20.0 vs. 23.5 months). A higher response rate 
and longer PFS were also observed in the OPUS [39] and PRIME [40] studies. In PRIME, 
median survival was non-significantly prolonged (19.7 vs. 23.9 months) at the same level as 
in the CRYSTAL trial. In the large COIN study only response rate was increased [41] and in 
the smaller NORDIC VII trial cetuximab did not improve efficacy of the Nordic bolus 
regimen [42]. 
Since addition of cetuximab or panitumumab improve response rate to combination 
chemotherapy, there has been a particular interest in the use of these agents in patients with 
potential resectable liver-only metastasis if it was anticipated that a major response could 
lead to potentially curative surgery. In the CELIM study, a randomized phase II trial with 
111 patients with unresectable liver- metastasis, patients were randomized to FOLFOX + 
cetuximab or FOLFIRI + cetuximab [43]. In these selected patients the R0 resection rate was 
impressing 38% and 30%, respectively, which show the importance of selecting and 
evaluation patients at a multidisciplinary conference but also that the patients should 
receive the most effective systemic therapy to enhance the chance for curative surgery. In a 
retrospective analysis of response by KRAS status, a partial or complete response was noted 
in 70% of patients with KRASwt.  
When cetuximab or panitumumab is chosen for patients with KRASwt, it must be 
concluded, that  the chemotherapy combination should be carefully selected. A combination 
of fluoropyrimidine with oxaliplatin and cetuximab seem to have no or less additional  
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Author. year Regimen KRAS 
No of 
patients 
RR 
(%) 
Median 
PFS 
(months) 
Median OS 
(months) 
First line therapy 
CRYSTAL 
van Cutsem et al 
NEJM 2009 & 
JCO 2011 
FOLFIRI WT 350 40 8.4 20.0 
FOLFIRI+Cet WT 316 57* 9.9* 23.5* 
FOLFIRI MUT 183 36 7.7 16.7 
FOLFIRI+Cet MUT 214 31 7.4 16.2 
PRIME 
Douillard et al 
JCO 2010 
FOLFOX WT 331 48 8.0 19.7 
FOLFOX+Pan WT 325 55 9.6* 23.9 
FOLFOX MUT 219 40 8.8* 19.3* 
FOLFOX+Pan MUT 221 40 7.3 15.5 
NORDIC 7 
Tveit et al 
ASCO GI 2011 
FLOX WT 97 47 8.7 20.1 
FLOX + Cet WT 97 46 7.9 22.0 
FLOX MUT 58 40 7.8 20.4 
FLOX + Cet MUT 72 49 9.2 21.1 
COIN 
Maughan et al 
Lancet Oncol 2011 
“Ox” WT 367 50 8.6 17.9 
“Ox”+Cet WT 362 59* 8.6 17.0 
“Ox” MUT 268 41 6.9 14.8 
“Ox”+ Cet MUT 297 40 6.5 13.6 
OPUS 
Bokemeyer et al 
Ann Oncol 2011 
FOLFOX WT 97 34 7.2 18.5 
FOLFOX + Cet WT 82 57* 8.3* 22.8 
FOLFOX MUT 59 53* 8.6* 17.5 
FOLFOX + Cet MUT 77 34 5.5 13.4 
Second line therapy  
181 
Peeters et al 
ECCO 2009 
FOLFIRI WT 294 10 3.9 12.5 
FOLFIRI+Pan WT 303 35* 5.9* 14.5 
FOLFIRI MUT 248 14 4.9 11.1 
FOLFIRI+Pan MUT 238 13 5.9 11.8 
Table 2. Recent studies evaluating EGFR-inhibition (cetuximab or panitumumab) as first line 
therapy according to KRAS-status. 
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benefit over chemotherapy alone [41,42] and presently capecitabine or bolus 5-fluorouracil 
in combination with oxaliplatin can not be recommended outside clinical trials (Table 2). 
Until otherwise proven, cetuximab or panitumumab should be combined with FOLFIRI or 
FOLFOX. 
7.1 Combinations of targeted therapies 
In vitro studies have shown that simultaneous inhibition of angiogenesis and EGFR systems 
have additive and perhaps even synergistic effect, but surprisingly this benefit could not be 
confirmed in first line randomised studies (Table 3).  
In a small randomised phase II study, a triple-combination of cetuximab, irinotecan and 
bevacizumab was more effective than cetuximab + bevacizumab alone [44].  Even more 
interesting, PFS and survival for the triple-combination were considerably longer than the 
historical double-combination in the BOND1 trial [34]. It was therefore expected that a 
similar combination would increase efficacy also as first line therapy.  
 
Author. year Regimen KRAS 
No of 
patients 
RR 
(%) 
Median 
PFS 
(months) 
Median OS 
(months) 
CAIRO2 
Tol et al 
NEJM 2009 
CapOx+Bev WT 156 50 10.6 22.4 
CapOx+Bev+Cet WT 158 61 10.5 21.8 
CapOx+Bev MUT 108 59* 12.5* 24.9* 
CapOx+Bev+Cet MUT 98 46 8.3 17.2 
PACCE 
Hecht et 
JCO 2009 
“Ox”+Bev WT 203 56 11.5* 24.5* 
“Ox”+Bev+Pan WT 201 50 9.8 20.7 
“Ox”+Bev MUT 125 44 11.0 19.3 
“Ox”+Bev+Pan MUT 135 47 10.5 19.3 
“Ir”+Bev WT 58 48 12.5 19.8 
“Ir”+Bev+Pan WT 57 54 10.0 NR 
“Ir”+Bev MUT 39 38 11.9 20.5 
“Ir”+Bev+Pan MUT 47 30 8.3 17.8 
Abbreviations in the tables: 
RR = response rate, PFS = progression free survival, OS = overall survival, BSC = best supportive care, 
cet = cetuximab, pan = panitumumab, WT = wildtype, mut = mutant, iri = irinotecan, ox = oxaliplatin, 
bev = bevazicumab 
Table 3. Recent studies evaluating double targeted therapy (inhibition of angiogenesis and 
EGFR) according to KRAS-status. 
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In the PACCE study more than 1000 patients were randomised to a combination of 
chemotherapy with bevacizumab (optional oxaliplatin-based regimen (n = 823) or 
irinotecan-based regimen (n = 230) with or without panitumumab [45]. The four-drug 
combination of oxaliplatin-based therapy with bevacizumab and panitumumab resulted in 
several serious adverse events and also a shorter PFS and survival, while there was no 
significant difference in efficacy data in the smaller group where therapy was based on 
irinotecan. Even in patients with KRAS wild-type there was evidence of a harmful effect of 
double targeted therapy.  
In the CAIRO-2 study, 734 patients were randomised to XELOX + bevacizumab with or 
without cetuximab. Similar to PACCE study, PFS was significantly shorter in patients 
receiving double targeted therapy and subgroup analysis of patients with KRAS mutations 
showed that efficacy (response, PFS and survival) was significant worse [46]. 
Double targeted therapy against angiogenesis and EGFR should not be used as first line 
treatment outside of controlled studies.  
8. Weekly or biweekly cetuximab 
Cetuximab is approved as weekly administration with an initial loading dose of 400 mg/m2 
followed by weekly administration of 250 mg/m2. However, as most cytotoxic regimens are 
administered in two-weeks (or longer) schedules it would be more convenient if cetuximab 
could be administered as a two-week schedule.  Based on a study showing that there is no 
major differences in the pharmacokinetics and pharmacodynamics between the standard 
weekly cetuximab schedule and cetuximab 500 mg/m2 given every second week [47,48] a 
simplified biweekly administration schedule of cetuximab has been developed [47-49]. The 
biweekly regimen has efficacy and safety profile similar to the weekly schedule [49-52] and 
ongoing studies will prospectively evaluate the biweekly regimen (www.clinicaltrial.org 
NCT00660582). In many institutions the biweekly schedule is used in the daily clinical 
setting based on the above-mentioned experiences. 
Panitumumab is administered as an intravenous infusion at 6 mg/kg every 14 days or 9 
mg/kg every 3 weeks. There is no loading dose. 
9. Toxicity of anti-EGFR therapy 
Toxicity of the anti-EGFR therapy is related to the blockade of the EGFR in the normal 
tissue. The most often reported side-effect is a papulo-pustular rash primarily in the 
seborrheic areas seen in up to 90% of patients [6].  The onset is usually within the first three 
weeks after start of therapy and with spontaneous improvement within the next 4–5 weeks 
[53]. Most cases are mild to moderate but severe in 5% to 20% of patients [6,7,34,35,54]. 
Prophylactic treatment with systemic tetracyclines reduces the severity of skin reactions but 
not the incidence of rash [55-57].Other dermatological reactions are xerosis, fissures of palm 
and foot, paronychia and extensive growth of both eyelashes and eyebrows [53,54,58,59], 
but these side-effects are primarily seen after many months of exposure to anti-EGFR 
therapy. 
Furthermore, cetuximab and panitumumab may induce severe hypomagnesaemia in as 
many as 25% of patients, but fortunately it is seldom symptomatic. Hypomagnesaemia 
results from inhibition of the EGFR in the kidneys - particularly in the ascending limb of the 
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loop of Henle. The hypomagnesaemia may be corrected by oral or IV supplements [60,61]. 
Anti-EGFR antibody therapy may as well cause nausea and diarrhea due to affection of the 
EFGR in the gastro-intestinal tract [34]. 
In addition, administration of chimeric antibodies also may give rise to severe allergic 
reactions in 1.4-4.5% [3]. The incidence of infusion reactions is reduced by the prophylactic 
use of antihistamines and corticosteroids as premedication [62]. No study has compared 
side effects of cetuximab and panitumumab, but cross-trial comparison shows that the 
spectrum of side effects is similar. However, as panitumumab is a human antibody 
anaphylactic reactions are rarely seen with panitumumab, and treatment with panitumu-
mab does not require premedication [63]. A switch to panitumumab may be used after 
severe hypersensitivity reaction to cetuximab [64-66].  
10. Conclusion 
Optimal therapy of patients with CRC has increased in complexity with the introduction of 
targeted therapies, but unfortunately our expectations for these new drugs have not quite 
been settled. The largest benefits have been achieved with modern chemotherapy, which 
remains the backbone of treatment of patients with mCRC. However, targeted therapy has 
clinically significant effect, but we must learn to identify the correct regimes for the right 
patients. KRAS status is currently the most important predictive marker for efficacy of anti-
EGFR therapy. To ensure the optimal treatment strategy, every patient with mCRC must be 
assessed by a multidisciplinary team.  
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